This page uses content from Wikipedia and is licensed under CC BY-SA.

Anatumomab mafenatox

Anatumomab mafenatox
Monoclonal antibody
TypeFab fragment
Clinical data
ATC code
  • none
CAS Number
  • none

Anatumomab mafenatox is a mouse monoclonal antibody studied for the treatment non-small cell lung cancer,[1] which acts as a tumor-targeted superantigen.[2]

It is a fusion protein of a human tumor-associated 5T4 antigen monoclonal IgG1 Fab fragment with an enterotoxin ('mafenatox') of Staphylococcus aureus.[3]

Development was abandoned in 2005.[4]


  1. ^ "Active Biotech". Retrieved 25 May 2016.
  2. ^ Hedlund, Gunnar; Forsberg, Göran; Nederman, Thore; Sundstedt, Anette; Dahlberg, Leif; Tiensuu, Mikael; Nilsson, Mats (2013). "Tumor-Targeted Superantigens": 365–381. doi:10.1002/9781118354599.ch24. Cite journal requires |journal= (help)
  3. ^ "Drug info" (PDF). World Health Organisation. Retrieved 25 May 2016.
  4. ^ []